Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rangering i aksjer #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Aksjekurs
$0.16328419
Markedsverdi
$204.14K
Endring (1 dag)
4.35%
Endring (1 år)
102.45%
Land
GB
Handel Fusion Antibodies plc (FAB)

Kategori

Inntekter for Fusion Antibodies plc (FAB)
Inntekter i Sep 2025 TTM: $-2.06M
Ifølge Fusion Antibodies plc sine nyeste økonomiske rapporter er selskapets nåværende resultat $-2.06M. I 2024 hadde selskapet et resultat på $-2.89M, en økning sammenlignet med resultatet i 2023, som var $-3.53M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Fusion Antibodies plc fra 2013 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $-2.06M -10.23%
2025 $-2.30M -20.56%
2024 $-2.89M -18.12%
2023 $-3.53M 101.40%
2022 $-1.75M 0.58%
2021 $-1.74M 30.88%
2020 $-1.33M -31.84%
2019 $-1.95M 95.89%
2018 $-997.05K -731.20%
2017 $157.96K 304.33%
2016 $39.07K -126.49%
2015 $-147.46K -26.55%
2014 $-200.78K -72.11%
2013 $-719.78K 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$20.46B -992,770.77%
DK
$4.64B -225,408.48%
US
$5.23B -253,916.57%
US
$2.14B -103,830.35%
BE
$1.45B -70,512.80%
NL